| Korea Biomedical Review | Eisai gets insurance coverage for thyroid cancer drug Korea Biomedical Review "We expect [the drug] will be recognized for its effectiveness in the market as the first line of treatment for radioactive iodine-refractory differentiated thyroid cancer," said Eisai Korea CEO Charlie Hongbyung Ko. The drug's efficacy was ... Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 CongressMarkets Insider all 2 news articles » |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vP5Gk9
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,